Skip to main content
Erschienen in: Clinical Rheumatology 7/2018

28.05.2018 | Brief Report

Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis

verfasst von: El Hakem Matraiah, Nkiruka Olisaka, Mariana Philipos, David Walbaum, Paula Dospinescu, Nicholas Fluck, Neil Basu, Dana Kidder

Erschienen in: Clinical Rheumatology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Immunosuppression in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by increasing risk of infections including opportunistic infections like Pneumocystis jirovecii pneumonia (PJP). Available evidence on risk factors and indications for prophylaxis in AAV is derived from PJP occurring early in the course of AAV. In this retrospective study, we characterized the profile of PJP in patients with AAV. PJP cases were identified retrospectively based on positive polymerase chain reaction test from electronic record followed by confirmation from medical records over a 10-year period. AAV patients without PJP over the same period were used as control group. Sixteen PJP+AAV+ were identified; in 14 of them, we were able to confirm they received PJP prophylaxis during induction therapy, while in two cases, data were missing. The onset of the infection was after 6 months from AAV diagnosis in 80% of cases. Escalations in immunosuppression prior to PJP were observed in six cases within 3 months prior to PJP onset. Overall mortality was 12.5%. By univariate analysis, renal involvement at AAV diagnosis was associated with PJP. These results indicate that PJP is not limited to the first 6 months following AAV diagnosis. Late-onset infection can occur in context of augmented immunotherapy, particularly with concurrent lymphopenia. Other risk factors that can independently predict late-onset PJP remain to be identified.
Literatur
1.
Zurück zum Zitat Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606CrossRefPubMedPubMedCentral Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kronbichler A, Jayne DRW, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig 45:346–368CrossRef Kronbichler A, Jayne DRW, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig 45:346–368CrossRef
4.
Zurück zum Zitat Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, for the European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494. https://doi.org/10.1136/ard.2010.137778 CrossRefPubMed Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K, for the European Vasculitis Study Group (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494. https://​doi.​org/​10.​1136/​ard.​2010.​137778 CrossRefPubMed
5.
Zurück zum Zitat Grotz W, Wanner C, Rother E, Schollmeyer P (1995) Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 69:234–236CrossRefPubMed Grotz W, Wanner C, Rother E, Schollmeyer P (1995) Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 69:234–236CrossRefPubMed
6.
Zurück zum Zitat Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D, EUVAS investigators (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://doi.org/10.1136/annrheumdis-2011-200477 CrossRefPubMed Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D, EUVAS investigators (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://​doi.​org/​10.​1136/​annrheumdis-2011-200477 CrossRefPubMed
8.
Zurück zum Zitat Wolfe RM, Peacock JE (2017) Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep 19:35CrossRefPubMed Wolfe RM, Peacock JE (2017) Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep 19:35CrossRefPubMed
10.
Zurück zum Zitat Aasarod K, Iversen BM, Hammerstrom J et al (2000) Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15:611–618CrossRefPubMed Aasarod K, Iversen BM, Hammerstrom J et al (2000) Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15:611–618CrossRefPubMed
14.
Zurück zum Zitat Jones R, Harper L, Ballarin J, Blockmans D, Brogan P, Bruchfeld A, Cid M, Dahlsveen K, Dezoysa J, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Jayne D (2013) A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group. Presse Med 42:678–679. https://doi.org/10.1016/j.lpm.2013.02.067 CrossRef Jones R, Harper L, Ballarin J, Blockmans D, Brogan P, Bruchfeld A, Cid M, Dahlsveen K, Dezoysa J, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Jayne D (2013) A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group. Presse Med 42:678–679. https://​doi.​org/​10.​1016/​j.​lpm.​2013.​02.​067 CrossRef
17.
Zurück zum Zitat Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594. https://doi.org/10.1136/annrheumdis-2016-209133 CrossRefPubMed Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594. https://​doi.​org/​10.​1136/​annrheumdis-2016-209133 CrossRefPubMed
18.
Zurück zum Zitat Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L (2017) Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol 35:671–673PubMed Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L (2017) Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol 35:671–673PubMed
20.
Zurück zum Zitat Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 71:5–13CrossRefPubMed Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 71:5–13CrossRefPubMed
Metadaten
Titel
Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis
verfasst von
El Hakem Matraiah
Nkiruka Olisaka
Mariana Philipos
David Walbaum
Paula Dospinescu
Nicholas Fluck
Neil Basu
Dana Kidder
Publikationsdatum
28.05.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 7/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4155-6

Weitere Artikel der Ausgabe 7/2018

Clinical Rheumatology 7/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.